Morgan Stanley Call 200 MDGL 20.0.../ DE000MG0KA78 /
06/06/2024 10:59:42 | Chg.+0.08 | Bid06/06/2024 | Ask06/06/2024 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
1.70EUR | +4.94% | 1.70 Bid Size: 1,000 |
1.80 Ask Size: 1,000 |
Madrigal Pharmaceuti... | 200.00 USD | 20/09/2024 | Call |
GlobeNewswire
05/06
Madrigal Pharmaceuticals to Participate in the Goldman Sachs 45th Annual Global Healthcare Conferenc...
GlobeNewswire
29/05
Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) and Health Economics Outcomes R...
GlobeNewswire
07/05
Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
GlobeNewswire
23/04
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, ...
GlobeNewswire
16/04
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
09/04
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of...
GlobeNewswire
05/04
US Gastroenterologists Project Swift Uptake of Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) for ...
GlobeNewswire
03/04
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
19/03
Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering
GlobeNewswire
14/03
FDA’s Approval of Breakthrough NASH Treatment Opens Door for a Long-Neglected Patient Population
GlobeNewswire
14/03
Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Pati...
GlobeNewswire
06/03
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
05/03
Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Res...
GlobeNewswire
28/02
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Fi...
GlobeNewswire
21/02
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
08/02
Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in th...
GlobeNewswire
06/02
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)